009290.KS
Kwang Dong Pharmaceutical Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 6,340.00
+0.79%Year over year
Reported trailing growth
- Revenue
- +5.5%
- EBITDA
- —
- EBIT
- +111.3%
- EPS
- -26.0%
- Free cash flow
- +165.3%
- Operating cash flow
- -70.5%
Forward estimates
Based on analyst estimates
- Revenue
- -41.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.0%
- EBITDA
- -3.5%
- EBIT
- -6.7%
- Net income
- -4.6%
- EPS
- -4.0%
- Free cash flow
- +15.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026